Benefits and risks of adjuvant treatment with zoledronic acid in stage II/III breast cancer. 10 years follow-up of the AZURE randomized clinical trial (BIG 01/04).

Coleman, R.E., Collinson, M., Gregory, W. et al. (20 more authors) (2018) Benefits and risks of adjuvant treatment with zoledronic acid in stage II/III breast cancer. 10 years follow-up of the AZURE randomized clinical trial (BIG 01/04). JOURNAL OF BONE ONCOLOGY, 13. pp. 123-135. ISSN 2212-1374

Abstract

Metadata

Authors/Creators:
  • Coleman, R.E.
  • Collinson, M.
  • Gregory, W.
  • Marshall, H.
  • Bell, R.
  • Dodwell, D.
  • Keane, M.
  • Gil, M.
  • Barrett-Lee, P.
  • Ritchie, D.
  • Bowman, A.
  • Liversedge, V.
  • De Boer, R.H.
  • Passos-Coelho, J.L.
  • O'Reilly, S.
  • Bertelli, G.
  • Joffe, J.
  • Brown, J.E.
  • Wilson, C.
  • Tercero, J.C.
  • Jean-Mairet, J.
  • Gomis, R.
  • Cameron, D.
Copyright, Publisher and Additional Information: © 2018 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/BY-NC-ND/4.0/).
Dates:
  • Accepted: 16 September 2018
  • Published (online): 27 September 2018
  • Published: 1 November 2018
Institution: The University of Sheffield
Academic Units: The University of Sheffield > Sheffield Teaching Hospitals
Depositing User: Symplectic Sheffield
Date Deposited: 04 Mar 2019 14:32
Last Modified: 05 Mar 2019 01:37
Published Version: https://doi.org/10.1016/j.jbo.2018.09.008
Status: Published
Publisher: Elsevier
Refereed: Yes
Identification Number: https://doi.org/10.1016/j.jbo.2018.09.008
Related URLs:

Share / Export

Statistics